|
|
|
|
|
Address 1
Address 2
City, State Zip
P xxx.xxx.xxxx
www.Allergan.com
|
Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders of Allergan in connection with the proposed transactions,
including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the Scheme Document when it is filed with the SEC. Information regarding Allergans directors and executive officers is
contained in Allergans Annual Report on Form
10-K
for the fiscal year ended December 31, 2018 and its Proxy Statement on Schedule 14A, dated March 22, 2019, which are filed with the SEC, and
certain of Allergans Current Reports on Form
8-K,
filed with the SEC on February 19, 2019, March 22, 2019 and May 1, 2019.
FORWARD-LOOKING STATEMENTS
This communication contains
certain forward-looking statements with respect to a possible acquisition involving AbbVie and Allergan and/or the combined groups estimated or anticipated future business, performance and results of operations and financial condition,
including estimates, forecasts, targets and plans for AbbVie and, following the acquisition, if completed, the combined group. The words believe, expect, anticipate, project and similar expressions,
among others, generally identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such
risks and uncertainties include, but are not limited to, the possibility that a possible acquisition will not be pursued, failure to obtain necessary regulatory approvals or required financing or to satisfy any of the other conditions to the
possible acquisition, adverse effects on the market price of AbbVies shares of common stock or Allergans ordinary shares and on AbbVies or Allergans operating results because of a failure to complete the possible acquisition,
failure to realize the expected benefits of the possible acquisition, failure to promptly and effectively integrate Allergans businesses, negative effects relating to the announcement of the possible acquisition or any further announcements
relating to the possible acquisition or the consummation of the possible acquisition on the market price of AbbVies shares of common stock or Allergans ordinary shares, significant transaction costs and/or unknown or inestimable
liabilities, potential litigation associated with the possible acquisition, general economic and business conditions that affect the combined companies following the consummation of the possible acquisition, changes in global, political, economic,
business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax laws, regulations, rates and policies, future business acquisitions or disposals and competitive developments. These forward-looking statements
are based on numerous assumptions and assessments made in light of AbbVies or, as the case may be, Allergans experience and perception of historical trends, current conditions, business strategies, operating environment, future
developments and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The
factors described in the context of such forward-looking statements in